Paul Kelly
Managing Partner
Pharmaceuticals
Vaxxas Nanopatch
Australia
Biography
Paul has over recent years assisted and led early-stage and mid-stage companies achieve business results in order to attract funding and transform their ideas, technologies and products into sustainable successful businesses. Paul is currently Chair on the Boards of OneVentures investee companies Vaxxas and Hatchtech and is non-executive director of Charmhealth. He is also non-executive director of Agamatrix Inc. Paul joined the OneVentures team in June 2008. Prior to joining OneVentures, Paul was CEO of Medcenter Holdings Inc. a Latin America based on-line pharmaceutical marketing company, a position he held until December 2007. Previously he served as President and CEO of Orchid Cellmark (Nasdaq:ORCH), the worlds leading provider of genetic testing services, from June 2003 until March 2006. During his tenure at both companies he developed and implemented major operational and strategic restructurings. From 1995 to 2001, Dr. Kelly served as CEO of Gemini Genomics (Nasdaq:GMNI), a clinical genomics company which he co-founded in 1995 to discover and commercialize novel gene-based targets.
Research Interest
Research Interest On Pharmaceuticals
